| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | Director | Stock Option (right to buy) | 30,000 | 17 Jun 2024 | Direct | ||
| Senti Biosciences, Inc. | Director | Stock Option (Right to Buy) | 21,950 | 25 Jun 2025 | Direct | ||
| Orion Biotech Opportunities Corp. | Director | Class B ordinary shares | 0 | 17 May 2023 | Direct |